Such insights may come from analyzes of other ongoing clinical trials of single-agent checkpoint blockade in NHL, including phase 2 studies of PD-1 blockade in DLBCL and FL (e.g., NCT02038946, NCT02038933, NCT03586024, and NCT03316573). Here, PDCD1 is linked to non-Hodgkin lymphoma.